![](https://medfyle.com/articles/06-racial-and-ethnic-disparity-and-predictors-of-hepatic-steatosis-in-nhanes/download_file?filename=articles%2F346_libraryimage.png)
![](https://medfyle.com/files/organizations/Endocrine_Society.png)
Trends in the Racial and Ethnic Disparity and Predictors of Hepatic Steatosis: Data From NHANES III and NHANES 2017-2018
In this medfyle
Expert commentary by Diana Barb, MD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ENDO 2021 and presented by:
Magda Shaheen, MD, MPH, PhD
Charles R Drew University
Los Angeles, CA, United States
The content is produced by Infomedica, the official reporting partner of ENDO 2021. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Raghu Mirmira, MD, PhD, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Diana Barb, MD
University of Florida
Gainesville, FL
About the Expert
Diana Barb, MD
University of Florida
Gainesville, FL
Dr. Diana Barb received her medical degree from the University of Medicine and Pharmacy in Targu Mures Romania. She did a two year research fellowship, focusing on obesity, and adipokines at Beth Israel Deaconess Medical Center, Harvard MedicalSchool in Boston, Massachusetts, followed by Internal Medicine Residency and Endocrinology Fellowship at Emory University in Atlanta, Georgia. Subsequently, she joined the University of Florida as a Clinical Assistant Professor in the Division of Endocrinology, Diabetes & Metabolism where she practices general endocrinology. Dr. Diana Barb is board certified in internal medicine (ABIM), general endocrinology, and obesity medicine (ABOM). Her research areas of specialization are in obesity and metabolism, with a particular focus on nonalcoholic fatty liver disease (NAFLD). She has been a co-investigator in clinical trials in NAFLD and contributing to work trying to understand underlying mechanisms of NAFLD.
References
1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-95.
2. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20.